Matches in SemOpenAlex for { <https://semopenalex.org/work/W2055872400> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2055872400 endingPage "A407" @default.
- W2055872400 startingPage "A407" @default.
- W2055872400 abstract "To identify the chemotherapeutic treatment patterns and associated costs in patients with chronic lymphocytic leukemia (CLL) in the Private Healthcare System. A retrospective analysis of the Orizon database, containing inpatient and outpatient claims data of a pool of 102 HMOs (34% of the total Private Health System), from January 2009 to December 2012 was conducted. Eligibility criteria were patients starting CLL (ICD-10 code C911) chemotherapy treatment from April 2009 to December 2012. This cohort of patients was followed until December 2012, death or loss of follow-up. Chemotherapy regimens were identified based on the agents reported in the claims. Line of treatment was defined based on meaningful interruption (>6 months) and/or change in the chemotherapy regimen. Descriptive statistics (average, standard deviation and percentage) of treatment regimens, duration of treatment and costs were performed. A total of 163 patients representing 859 cycles of chemotherapy met eligibility criteria; 43.6% of the patients underwent more than one line of treatment, with total chemotherapy costs of R$84,979.63 per patient. The three most widely used chemotherapy regimen were: fludarabine, cyclofosfamide and rituximab (FCR), used in 81 (54.9%) patients with average treatment duration of 3.54 cycles and total costs of R$69,241.91 per patient; rituximab monotherapy, used in 44 (27.0%) patients, with average treatment duration of 4.05 cycles and total costs of R$59,543.12 per patient; and fludarabine and cyclofosfamide (FC), used in 19 (11.7%) patients, with average duration of 2.22 cycles and total costs of R$7,075.95 per patient. Chemotherapy drugs accounted for 72.8% of the total costs, followed by other medicines (11%), disposable devices (5.5%) and hospital facility fees (5.0%). FCR is the standard of care in CLL patients treated in the Brazilian Private Health System, and almost half of the patients undergo more than one treatment line, creating a significant financial burden to private payers." @default.
- W2055872400 created "2016-06-24" @default.
- W2055872400 creator A5016036237 @default.
- W2055872400 creator A5040321862 @default.
- W2055872400 creator A5049122521 @default.
- W2055872400 creator A5051379367 @default.
- W2055872400 creator A5087349294 @default.
- W2055872400 date "2013-11-01" @default.
- W2055872400 modified "2023-09-29" @default.
- W2055872400 title "Treatment Patterns and Costs Associated with Chronic Lymphocytic Leukemia Chemotherapy Under the Brazilian Private Health Care Perspective: A Retrospective Analysis of the Orizon Database" @default.
- W2055872400 doi "https://doi.org/10.1016/j.jval.2013.08.484" @default.
- W2055872400 hasPublicationYear "2013" @default.
- W2055872400 type Work @default.
- W2055872400 sameAs 2055872400 @default.
- W2055872400 citedByCount "0" @default.
- W2055872400 crossrefType "journal-article" @default.
- W2055872400 hasAuthorship W2055872400A5016036237 @default.
- W2055872400 hasAuthorship W2055872400A5040321862 @default.
- W2055872400 hasAuthorship W2055872400A5049122521 @default.
- W2055872400 hasAuthorship W2055872400A5051379367 @default.
- W2055872400 hasAuthorship W2055872400A5087349294 @default.
- W2055872400 hasBestOaLocation W20558724001 @default.
- W2055872400 hasConcept C126322002 @default.
- W2055872400 hasConcept C141071460 @default.
- W2055872400 hasConcept C167135981 @default.
- W2055872400 hasConcept C187212893 @default.
- W2055872400 hasConcept C2776694085 @default.
- W2055872400 hasConcept C2776755627 @default.
- W2055872400 hasConcept C2777938653 @default.
- W2055872400 hasConcept C2778336483 @default.
- W2055872400 hasConcept C2778461978 @default.
- W2055872400 hasConcept C2779263901 @default.
- W2055872400 hasConcept C2779338263 @default.
- W2055872400 hasConcept C2780653079 @default.
- W2055872400 hasConcept C2781413609 @default.
- W2055872400 hasConcept C71924100 @default.
- W2055872400 hasConceptScore W2055872400C126322002 @default.
- W2055872400 hasConceptScore W2055872400C141071460 @default.
- W2055872400 hasConceptScore W2055872400C167135981 @default.
- W2055872400 hasConceptScore W2055872400C187212893 @default.
- W2055872400 hasConceptScore W2055872400C2776694085 @default.
- W2055872400 hasConceptScore W2055872400C2776755627 @default.
- W2055872400 hasConceptScore W2055872400C2777938653 @default.
- W2055872400 hasConceptScore W2055872400C2778336483 @default.
- W2055872400 hasConceptScore W2055872400C2778461978 @default.
- W2055872400 hasConceptScore W2055872400C2779263901 @default.
- W2055872400 hasConceptScore W2055872400C2779338263 @default.
- W2055872400 hasConceptScore W2055872400C2780653079 @default.
- W2055872400 hasConceptScore W2055872400C2781413609 @default.
- W2055872400 hasConceptScore W2055872400C71924100 @default.
- W2055872400 hasIssue "7" @default.
- W2055872400 hasLocation W20558724001 @default.
- W2055872400 hasOpenAccess W2055872400 @default.
- W2055872400 hasPrimaryLocation W20558724001 @default.
- W2055872400 hasRelatedWork W2044556191 @default.
- W2055872400 hasRelatedWork W2156693813 @default.
- W2055872400 hasRelatedWork W2362661449 @default.
- W2055872400 hasRelatedWork W2575619275 @default.
- W2055872400 hasRelatedWork W2792230705 @default.
- W2055872400 hasRelatedWork W2801454081 @default.
- W2055872400 hasRelatedWork W2913496777 @default.
- W2055872400 hasRelatedWork W2946618690 @default.
- W2055872400 hasRelatedWork W3032811446 @default.
- W2055872400 hasRelatedWork W4296964215 @default.
- W2055872400 hasVolume "16" @default.
- W2055872400 isParatext "false" @default.
- W2055872400 isRetracted "false" @default.
- W2055872400 magId "2055872400" @default.
- W2055872400 workType "article" @default.